Video

Addressing Cancer Health Disparities

Disparities in cancer care are predominantly due to access issues, states Jeffery C. Ward, MD. Removing barriers to access, such as socioeconomic, language, and cultural barriers, will help to eliminate disparities.

An important component of addressing the high cost of care in the United States is focusing more on population health, says Michael Kolodziej, MD. It is important for individuals to be screened for cancer and to maintain a healthy lifestyle. Improving population health is the primary intent behind quality metrics, adds Kolodziej.

As the demand for oncologists increases, so does the need for payment reform, notes Ward. It is also essential to address the way care is delivered, states Kolodziej. Team-based care, such as within a patient-centered medical home, allows healthcare professionals to operate at the top of their licenses. Working as part of a team diffuses some of the individual responsibilities, adds Kolodziej, and enriches the career paths of its members.

Related Videos
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.